MedTrace Logo

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-03-12

No results posted yet for this study

Summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Conditions

Interventions

DRUG

metformin hydrochloride 500 mg tablet

500-mg immediate release tablet PO

DRUG

rosuvastatin 10 mg tablet

10-mg tablet PO

DRUG

repaglinide 0.5 mg tablet

0.5-mg tablet PO

DRUG

midazolam hydrochloride syrup

2 mg dose (5-mg/2.5 mL syrup) PO

DRUG

rezatapopt

2000 mg dose (4 x 500-mg tablets) PO

Sponsors & Collaborators

  • SCRI Development Innovations, LLC

    collaborator OTHER

  • PMV Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Vivek Subbiah, MD · SCRI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-04
Primary Completion
2027-03-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07372625 on ClinicalTrials.gov